Sanders Morris Harris LLC Buys New Shares in argenex SE $ARGX

Sanders Morris Harris LLC purchased a new position in shares of argenex SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,830 shares of the company’s stock, valued at approximately $1,350,000.

Several other large investors have also added to or reduced their stakes in the company. WPG Advisers LLC purchased a new stake in argenex in the first quarter valued at approximately $37,000. Brooklyn Investment Group lifted its stake in argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after acquiring an additional 38 shares during the period. MAI Capital Management boosted its holdings in shares of argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of argenex in the first quarter worth $62,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Price Performance

Shares of ARGX stock opened at $851.42 on Wednesday. The stock has a 50 day simple moving average of $865.62 and a 200-day simple moving average of $722.06. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The company has a market cap of $52.42 billion, a price-to-earnings ratio of 36.56, a PEG ratio of 0.86 and a beta of 0.37.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. Analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ARGX shares. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Stifel Nicolaus boosted their price target on argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Royal Bank Of Canada raised their price objective on shares of argenex from $850.00 to $860.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Morgan Stanley boosted their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Finally, Zacks Research downgraded shares of argenex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average target price of $968.83.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.